Data Insights

SENL-101 by Hebei Senlang Biotechnology for Relapsed Acute Myeloid Leukemia: Likelihood of Approval

SENL-101 is under clinical development by Hebei Senlang Biotechnology and currently in Phase I for Relapsed Acute Myeloid Leukemia. According...

Likelihood of Approval and Phase Transition Success Rate Model - SENL-101 in Relapsed Acute Myeloid Leukemia

Data Insights

SENL-101 by Hebei Senlang Biotechnology for Refractory Acute Myeloid Leukemia: Likelihood of Approval

SENL-101 is under clinical development by Hebei Senlang Biotechnology and currently in Phase I for Refractory Acute Myeloid Leukemia. According...

Likelihood of Approval and Phase Transition Success Rate Model - SENL-101 in Refractory Acute Myeloid Leukemia

Data Insights

SENL-B19 by Hebei Senlang Biotechnology for Lymphoma: Likelihood of Approval

SENL-B19 is under clinical development by Hebei Senlang Biotechnology and currently in Phase II for Lymphoma. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - SENL-B19 in Lymphoma

Data Insights

SENL-B19 by Hebei Senlang Biotechnology for Non-Hodgkin Lymphoma: Likelihood of Approval

SENL-B19 is under clinical development by Hebei Senlang Biotechnology and currently in Phase II for Non-Hodgkin Lymphoma. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - SENL-B19 in Non-Hodgkin Lymphoma

Data Insights

SENL-B19 by Hebei Senlang Biotechnology for Leukemia: Likelihood of Approval

SENL-B19 is under clinical development by Hebei Senlang Biotechnology and currently in Phase II for Leukemia. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - SENL-B19 in Leukemia

Data Insights

CD19+22 CAR-T by Hebei Senlang Biotechnology for B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia): Likelihood of Approval

CD19+22 CAR-T is under clinical development by Hebei Senlang Biotechnology and currently in Phase II for B-Cell Acute Lymphocytic Leukemia...

Likelihood of Approval and Phase Transition Success Rate Model - CD19+22 CAR-T in B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia)

Data Insights

CD19+22 CAR-T by Hebei Senlang Biotechnology for Primary Mediastinal B-Cell Lymphoma: Likelihood of Approval

CD19+22 CAR-T is under clinical development by Hebei Senlang Biotechnology and currently in Phase II for Primary Mediastinal B-Cell Lymphoma....

Likelihood of Approval and Phase Transition Success Rate Model - CD19+22 CAR-T in Primary Mediastinal B-Cell Lymphoma

Data Insights

CD19+22 CAR-T by Hebei Senlang Biotechnology for Follicular Lymphoma: Likelihood of Approval

CD19+22 CAR-T is under clinical development by Hebei Senlang Biotechnology and currently in Phase II for Follicular Lymphoma. According to...

Likelihood of Approval and Phase Transition Success Rate Model - CD19+22 CAR-T in Follicular Lymphoma

Data Insights

CD19+22 CAR-T by Hebei Senlang Biotechnology for Diffuse Large B-Cell Lymphoma: Likelihood of Approval

CD19+22 CAR-T is under clinical development by Hebei Senlang Biotechnology and currently in Phase II for Diffuse Large B-Cell Lymphoma....

Likelihood of Approval and Phase Transition Success Rate Model - CD19+22 CAR-T in Diffuse Large B-Cell Lymphoma

Data Insights

SL-22P by Hebei Senlang Biotechnology for Refractory Brain Metastasis: Likelihood of Approval

SL-22P is under clinical development by Hebei Senlang Biotechnology and currently in Phase I for Refractory Brain Metastasis. According to...

Likelihood of Approval and Phase Transition Success Rate Model - SL-22P in Refractory Brain Metastasis

Data Insights

SL-22P by Hebei Senlang Biotechnology for Solid Tumor: Likelihood of Approval

SL-22P is under clinical development by Hebei Senlang Biotechnology and currently in Phase I for Solid Tumor. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - SL-22P in Solid Tumor

Data Insights

SL-22P by Hebei Senlang Biotechnology for Liver Cancer: Likelihood of Approval

SL-22P is under clinical development by Hebei Senlang Biotechnology and currently in Phase I for Liver Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - SL-22P in Liver Cancer

Data Insights

Senl-h19 by Hebei Senlang Biotechnology for B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia): Likelihood of Approval

Senl-h19 is under clinical development by Hebei Senlang Biotechnology and currently in Phase II for B-Cell Acute Lymphocytic Leukemia (B-Cell...

Data Insights

CD19+22 CAR-T by Hebei Senlang Biotechnology for Marginal Zone B-cell Lymphoma: Likelihood of Approval

CD19+22 CAR-T is under clinical development by Hebei Senlang Biotechnology and currently in Phase I for Marginal Zone B-cell Lymphoma....

Data Insights

CD19+22 CAR-T by Hebei Senlang Biotechnology for Refractory Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval

CD19+22 CAR-T is under clinical development by Hebei Senlang Biotechnology and currently in Phase I for Refractory Chronic Lymphocytic Leukemia...

Data Insights

CD19+22 CAR-T by Hebei Senlang Biotechnology for Relapsed Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval

CD19+22 CAR-T is under clinical development by Hebei Senlang Biotechnology and currently in Phase I for Relapsed Chronic Lymphocytic Leukemia...

Data Insights

CD19+22 CAR-T by Hebei Senlang Biotechnology for Burkitt Lymphoma: Likelihood of Approval

CD19+22 CAR-T is under clinical development by Hebei Senlang Biotechnology and currently in Phase I for Burkitt Lymphoma. According to...

Data Insights

CD19+22 CAR-T by Hebei Senlang Biotechnology for Mantle Cell Lymphoma: Likelihood of Approval

CD19+22 CAR-T is under clinical development by Hebei Senlang Biotechnology and currently in Phase I for Mantle Cell Lymphoma. According...

Data Insights

Gene Therapy to Target CD22 for Acute Lymphocytic Leukemia and Non-Hodgkin Lymphoma by Hebei Senlang Biotechnology for B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia): Likelihood of Approval

Gene Therapy to Target CD22 for Acute Lymphocytic Leukemia and Non-Hodgkin Lymphoma is under clinical development by Hebei Senlang Biotechnology...

Data Insights

SENL-002 by Hebei Senlang Biotechnology for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia): Likelihood of Approval

SENL-002 is under clinical development by Hebei Senlang Biotechnology and currently in Phase II for Acute Myelocytic Leukemia (AML, Acute...